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INTRODUCTION
Circulatory and cardiac 
d y s f u n c t i o n ,  c a u s e d  b y 
splanchnic vasodilation, was 
reported in patients with liver 
cirrhosis. The hyperdynamic 
circulation and the activation of 
potent vasoconstrictor systems 
may overload the heart [1-3].
Clinical and experimental 
s t u d i e s  h a v e  r e v e a l e d  a 
latent cardiac dysfunction, 
characterized by decreased 
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ABSTRACT
Background & Aims: ProBNP is a sensitive marker of cardiac dysfunction. We assessed the concentration 
of circulating NT-proBNP in patients with liver cirrhosis in various stages of the disease and its correlation 
with markers of cardiac and renal dysfunction and with markers of liver disease severity. 
Patients and methods: A number of 88 patients with liver cirrhosis were included in the study, divided into 3 
groups: group 1 – 18 control patients without ascites; group 2 – 35 non-azotemic patients with ascites; group 
3 – 35 patients with hepatorenal syndrome. e cardiac dysfunction was assessed by measuring the NT-
proBNP serum levels and the QTc interval. e markers of renal dysfunction were the estimated glomerular 
ltration rates – formulas involving creatinine and serum cystatin C. e Child-Pugh score was used to assess 
the liver disease severity.
Results: e median NT-proBNP serum levels signicantly increased in patients with advanced liver cirrhosis 
(group 3: 960 fmol/ml and group 2:  660 fmol/ml) as compared to group 1 (435 fmol/ml) (p<0.05). A signicant 
direct correlation was found between the NT-proBNP concentration and the QTc interval (r=0.540, p<0.001). 
e NT-proBNP levels also correlated with the Child-Pugh score (r=0.501, p<0.01), proving the link between 
the cardiac dysfunction and the liver disease severity. e cardio-renal interrelation is supported by the 
relationship between the NT-proBNP concentration and the estimated clearances.
Conclusion: e high NT-proBNP levels in patients with advanced cirrhosis indicate the presence of cardiac 
dysfunction, which has a role in the pathogenesis of the hepatorenal syndrome. 
Key words: liver cirrhosis – cirrhotic cardiomyopathy – proBNP – NT-proBNP – hepatorenal syndrome – 
cardio-renal dysfunction. 
Abbreviations: DP: diastolic pressure; GFR: glomerular ltration rate; HRS: hepatorenal syndrome; MAP: 
mean arterial pressure; NT-proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; 
proBNP: prohormone brain natriuretic peptide; SBP: spontaneous bacterial peritonitis; SP: systolic pressure; 
TIPS: tranjugular intrahepatic portosystemic shunt.
contractile response to stress, altered diastolic relaxation, and 
electrophysiological anomalies – QT interval prolongation, in 
the absence of any organic cardiac disease. All these alterations 
dene the cirrhotic cardiomyopathy [4, 5]. Cirrhotic patients, 
due to cardiac dysfunction, have impaired prognosis and 
a worse outcome during infections (spontaneous bacterial 
peritonitis, SBP) or during invasive procedures such as surgery, 
TIPS implantation or hepatic transplantation [6-8].
The cardiac dysfunction is frequently latent and only 
becomes apparent because of overexertion. e decreased 
systolic function diminishes the renal blood ow and sodium 
excretion, leading to severe complications such as: sodium 
and water retention, ascites and hepatorenal syndrome (HRS) 
[9]. e B-type natriuretic peptide (BNP) and its prohormone 
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(pro-BNP) are sensitive markers of ventricular dysfunction. 
Maintaining cardiac contractility is an important link in the 
prevention of renal dysfunction and HRS in patients with 
advanced liver cirrhosis [10, 11].
We aimed to assess the concentration of circulating NT-
proBNP in patients in various stages of liver cirrhosis and its 
value was correlated with the markers of cardiac dysfunction 
(mean arterial pressure, QT interval) and renal dysfunction 
(estimated glomerular ltration rate, GFR) and with markers 
of liver disease severity (Child-Pugh score).
PATIENTS AND METHODS
Eighty-eight patients diagnosed with liver cirrhosis on 
clinical, biochemical and morphological criteria were included 
in the study. ey were divided into 3 groups. Group 1 included 
18 patients (20.5%) as controls, i.e. with compensated liver 
cirrhosis, without ascites. The group 2 included 35 non-
azotemic cirrhotic patients (39.8%) with ascites and creatinine 
values < 1.5 mg/dl. In this group, 15 patients (42.8%) had 
moderate ascites (2nd degree) and 20 patients (57.1%) had 
massive ascites (3rd degree). Of these, 13 (37.1%) were 
diagnosed with spontaneous bacterial peritonitis (SBP). Group 
3 consisted of 35 patients (39.8%) with liver cirrhosis and HRS: 
17 patients (48.57%) had type 1 HRS and 18 patients (51.42%), 
type 2 HRS. Twenty patients (57.1%) of these had SBP.
No patient was on medication with betablockers, diuretics or 
albumin. ey were enrolled in the study at the admission in the 
hospital, and blood samples were taken before any medication.
e HRS diagnosis was established based on the 2007 
International Ascites Club criteria: cirrhosis with ascites; serum 
creatinine >1.5 mg/dl; no improvement of serum creatinine 
(decrease ≤ 1.5 mg/dL) after volume expansion; absence 
of shock; no treatment with nephrotoxic drugs; absence of 
parenchymal kidney disease as indicated by proteinuria >500 
mg/day, microhematuria (>50 RBCs/high power eld), and/
or abnormal renal ultrasound scanning [12]. 
Excluded from our study were the patients with: liver 
cirrhosis and kidney failure of other etiology than HRS; 
cardiac disease (ischemic heart disease, arterial hypertension, 
valvulopathy etc.); clinically obvious heart failure; recent 
gastrointestinal bleeding with hemodynamic instability; thyroid 
dysfunction (hypo or hyperthyroidism) and patients under 
treatment with corticosteroids or conversion enzyme inhibitors.
The cardiac dysfunction was assessed in the studied 
patients using the following parameters:
- mean arterial pressure MAP=(SP+2DP)/3 (SP – systolic 
pressure, DP – diastolic pressure);
- corrected QT interval (Qtc), calculated using the following 
formula: QTc (msec) = QT/(RR)
1/2, where QT – the measured 
QT interval, RR – the interval between two consecutive R-wave 
peaks. e result was divided by the predicted QT interval 
for the respective frequency (x%). e normal value of the 
QTc ranges between 90%-110% of the predicted QT for the 
respective frequency. A prolonged QTc interval was dened 
when it exceeded 110% of the predicted QT interval for the 
respective heart frequency;
- NT-proBNP concentration (the N-terminal fragment of 
the prohormone B-type natriuretic peptide) was measured 
using the Biomedica bio-enzyme test provided by Biomedica 
Medizinprodukte GmbH&CoKG (Wien, Austria). e method 
is based on a sandwich ELISA test. e normal value listed on 
the kit is <350 fmol/ml (average 250-350 fmol/ml).
e kidney function was assessed in the patients using the 
following parameters:
- serum creatinine;
- serum cystatin C. The “Quantikine Cystatin C” 
immunoenzymatic assay used in the measurement was 
provided by R&D Systems, Inc, Minneapolis, USA. The 
assay employs a quantitative immunoenzymatic technique 
(sandwich ELISA). e normal serum cystatin C value is 792 
± 161 ng/ml (ranges 553 – 1257 ng/ml);
- creatinine clearance, estimated using the MDRD 6 
equation; the calculator, available at the Internet address 
http://www.tinkershop.net/nephro.htm#gfr_levey, includes 6 
parameters (age, sex, race, serum creatinine, urea, albumin);
- estimated GFR from the serum cystatin C value, using 
the Hoek formula: eGFR (ml/min/1.73 m2) = -4.32 + 80.35/
Cys C (mg/l) [13].
e patients’ prognosis was assessed with the MELD score, 
calculated using bilirubin, INR and creatinine values of the 
patient (http://www.mayoclinic.org/meld/mayomodel5.htm).
Statistical analysis 
Statistical analysis was performed with the SPSS 16.0 
soware for Windows, Medcalc 10.3.0.0 (Demo Versions). 
The χ2 test was used in order to analyse the differences 
between the qualitative variables. e normality of distribution 
of continuous numerical variables was assessed with the 
Kolmogorov-Smirnov test. The differences between the 
means of continuous quantitative variables were evaluated 
with the Student t test, while for variables with non-normal 
distribution, non-parametric tests (Mann-Whitney U) were 
used. e ANOVA and Kruskal-Wallis tests were also used. A 
p value<0.05 was considered statistically signicant.
RESULTS
e clinical and demographic characteristics of the three 
patient groups are presented in Table I.
NT-proBNP concentration
e NT-proBNP values did not have a normal distribution 
and the results have been expressed as means. e highest mean 
value (960 fmol/ml) was found in HRS patients, signicantly 
higher than that found in cirrhotic patients without ascites (435 
fmol/ml) (p<0.05) and also than that of non-azotemic cirrhotic 
patients with ascites (660 fmol/ml) (p<0.05). Furthermore, the 
non-azotemic patients with ascites had signicantly higher 
values than the cirrhotic patients in the control group (p<0.05) 
(Table II). is suggests that the cardiac dysfunction was 
already present in the non-azotemic cirrhotic patients with 
ascites. e most severe heart dysfunction was recorded in the 
group of patients with HRS.
e median NT-proBNP value was signicantly increased 
in type 1 HRS patients (1080 fmol/ml) as compared to type 2 
HRS patients (940 fmol/ml) (p = 0.047).
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e median NT-proBNP value found in patients who died 
from the entire study group was higher than the median value 
of all surviving patients (1500 fmol/ml versus 660 fmol/ml) 
(p = 0.0025).
NT-proBNP concentration and etiology of liver cirrhosis 
e HRS group was divided into two subgroups, according 
to liver disease etiology: 16 patients had alcoholic cirrhosis and 
19 patients had viral cirrhosis. No signicant dierences of the 
NT-proBNP median values were found between the subgroups 
(1005 fmol/ml vs 960 fmol/ml). 
Two subgroups according to the etiology were also selected 
in patients with moderate or massive ascites: 20 patients 
with alcoholic cirrhosis and 15 patients with viral cirrhosis. 
No signicant dierences were recorded between these two 
subgroups, either (660 fmol/ml vs 690 fmol/ml).
QTc interval
An electrocardiogram at the admission, simultaneously 
performed with the blood tests was available in 46 patients. e 
number of the patients from each group was almost similar: 
14 patients of the controls (group 1), 17 patients of group 
2, and 15 patients of group 3. e group 3 (HRS patients) 
had the highest median QTc interval value, at a statistically 
signicant dierence from the control group (460.53 msec vs 
397.14 msec). In patients from group 2 the QTc interval was 
also signicantly increased as compared to the controls (452.35 
msec vs 397.14 msec) (Table II).
e proportion of patients with prolonged QTc interval 
was 35.7% in group 1, 82.4% in group 2 and 100% in group 3.
Correlation of the parameters of cardiac dysfunction 
NT-proBNP, the QTc interval and the MAP were selected 
as parameters of cardiac dysfunction. e correlation of the 
proBNP concentration with the other parameters of cardiac 
dysfunction was assessed and the following significant 
correlations were found: between NT-proBNP and the QTc 
interval (r=0.540; p<0.001), between proBNP and MAP (r= 
-0.377; p<0.001), between the QTc interval and MAP (r= 
-0.404; p=0.005). 
e strongest correlation (Fig. 1) was recorded between 
the NT-proBNP level and the QTc interval.
NT-proBNP concentration and liver disease severity
e liver disease severity was assessed using the Child-Pugh 
score. e NT-proBNP concentration was signicantly higher 
with each Child-Pugh point, correlating with the severity of 
the liver disease (Fig. 2) (r=0.501, p<0.01).
NT-proBNP concentration and markers of renal 
dysfunction
The kidney function parameters (serum cystatin C, 
creatinine clearance estimated with the MDRD6 formula, 








Age (mean ± 
SD, years)











Ascites n (%) - 35 (100%) 35 (100%)
SBP n (%) - 13 (37.1%) 20 (57.1%)
Encephalopathy 
n (%)
- 19 (54.3%) 21 (60%)
Table II. Parameters of cardiac and renal dysfunction and prognostic factors 























8.27±3.96 18.08±5.89 27.8±8.16 p*<0.0001 
p**<0.0001 
p***<0.0001
Cys C (ng/ml) 
median value






75.25±13.45 66.13±23.36 19.62±8.92 p*=0.1332 
p**<0.0001 
p***<0.0001
Cys Cl Hoek 
(ml/
in/1.73m2)
53.33±15.68 39.14±16.13 18.83±9.16 p*=0.0039 
p**=0.009 
p***=0.002
Group 1- cirrhotic patients without ascites; group 2 - non-azotemic cirrhotic 
patients with ascites; group 3 - cirrhotic patients with HRS; 
p* - comparison between groups 2 and 1; p**- comparison between groups 3 
and 1; p*** - comparison between groups 3 and 2
Fig. 1 Correlation between the NT-proBNP concentration and the QTc interval 
Legend: y= QTc interval (msec) 
              x= NT-proBNP (fmol/ml) 
Fig. 1. Correlation between the NT-proBNP concentration and the 
QTc interval. 
y= QTc interval ( sec); x= NT-proBNP (fmol/ml)
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serum cystatin C clearance estimated with the Hoek formula) 
are displayed in Table II. When studying the correlation 
between the NT-proBNP concentration and the estimated 
GFR, a signicant negative relationship was found (r=-0.505; 
p<0.01 with the estimated creatinine clearance using the 
MDRD 6 equation, and r=-0.575; p<0.01 with the estimated 
GFR using the Hoek formula derived from the serum cystatin 
C value).
Figure 3 presents the correlation between cardiac 
dysfunction (assessed by the NT-proBNP concentration) 
and renal dysfunction (estimated by the Cys Cl -Hoek). e 
NT-proBNP levels increased (cardiac dysfunction worsening) 
when the estimated clearance decreased (renal dysfunction 
worsening). 
NT-proBNP concentration and prognosis
e prognosis of the patients in the entire group was 
assessed using the MELD score (Table II). Figure 4 presents 
the correlation between NT-proBNP concentration and MELD 
score. The prognosis worsened as the NT-proBNP levels 
increased, indicating worsening of cardiac dysfunction.
arterial hypertension, valvulopathies, congenital cardiopathies, 
alcoholic cardiomyopathy, hemochromatosis etc.) The 
diagnosis is dicult to establish in basal conditions (even with 
the dobutamine stress test), because cardiac function is normal 
at rest. e disease can be tolerated for a long time, because the 
ventricular underlling due to splanchnic arterial vasodilation 
may mask the presence of ventricular failure. However, this is 
unmasked by physiologic or pharmacologic stress, bacterial 
infections (SBP) or aer surgery (TIPS placement or liver 
transplantation) [14, 15].
BNP and proBNP levels reect the presence of myocardial 
hypertrophy and cardiac dysfunction and are particularly 
useful in screening patients for cirrhotic cardiomyopathy. e 
BNP gene is expressed predominantly on the myocytes of the 
insucient le ventricle, leading to increased secretion of BNP 
to the circulation. e natriuretic peptides are synthesized as 
pre-prohormones with endocrinologically-active C-terminal 
peptides. e proteolytic cleavage of proBNP to N-terminal 
proBNP (1-76) and biologically-active C-terminal BNP takes 
place in the cardiomyocytes. e larger N-terminal fragments 
of the proBNP are more stable and have a longer plasma half-
life and thus a better detection prole as compared to the active 
C-terminal BNP hormone. ProBNP is a better indicator of 
cardiac dysfunction and its levels increase in symptomatic as 
well as asymptomatic latent heart failure [16, 17].
In cirrhotic patients, proBNP measurement may be 
impaired by its cleavage in smaller fragments and by alterations 
of its liver metabolism. e hepatic arteriovenous extraction 
of BNP and proBNP is not signicantly dierent in cirrhotic 
patients as opposed to healthy controls; in cirrhotic patients, 
the circulating levels of proBNP and BNP reect increased 
secretion in the cardiomyocytes, and not decreased hepatic 
uptake. The usual measurement methods of N-terminal 
proBNP (NT-proBNP) use antibodies targeted against 
specic epitopes of the N-terminal pro-peptide. ese allow 
the measurement of both the intact N-terminal fragments of 
proBNP (1-76) and the smaller N-terminal proBNP fragments 
(1-21), reecting the total circulating proBNP concentration 
[18, 19].
In patients with advanced liver cirrhosis, an increased 
concentration of BNP and proBNP was reported, reecting 
the cardiac dysfunction present in these patients. e proBNP 
levels are an even a better indicator of early cardiac dysfunction 
Fig.2 Correlation between the NT-proBNP (fmol/ml) concentration and the Child-
Pugh score 
Legend: y= NT-proBNP (fmol/ml) 
              x= Child-Pugh score 
Fig. 2. Correlation between the NT-proBNP (fmol/ml) concentration 
and the Child-Pugh score.
y= NT-proBNP (fmol/ml); x= Child-Pugh score
Fig. 3 Correlation between the NT-proBNP level and cystatin C clearance estimated 
with the Hoek formula 
Legend: y= Cys C clearance (ml/min/1.73m2)
               x= NT-proBNP (fmol/ml) 
Fig. 3. Correlation between the NT-proBNP level and cystatin C 
clearance esti ated with the Hoek formula
y= Cys C clearance (ml/min/1.73m2);  x= NT-proBNP (fmol/ml)
Fig.4 Correlation between the NT-proBNP level and the MELD score
Legend:  y= NT-proBNP (fmol/ml) 
                x=MELD score 
Fig. 4. Correlation between the NT-proBNP level and the MELD 
score. 
 y= NT-proBNP (fmol/ml); x=MELD score
DISCUSSION
e diagnosis of cirrhotic cardiomyopathy is established 
aer exclusion of other cardiopathies (ischemic heart disease, 
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than BNP levels. e rst study to report an increase in proBNP 
concentration in cirrhotic patients was published by Henriksen 
et al, who also reported the correlation between the serum 
levels of cardiac peptides with markers of liver disease severity, 
of cardiac and renal dysfunction [19, 20].
e patients with HRS have a decreased renal blood ow, 
GFR and sodium excretion, which appear to be correlated to 
the decrease in systolic function [21]. In our study, the NT-
proBNP levels in the HRS group were signicantly higher 
than in the non-azotemic patients with ascites; the latter were 
also signicantly higher than in the patients without ascites. 
ese ndings reveal the presence of a cardiac dysfunction not 
only in HRS patients, but also in non-azotemic patients with 
advanced liver cirrhosis and ascites. Seven out of the 8 patients 
with the highest NT-proBNP values (over 1500 fmol/ml) had 
the lowest values of estimated GFR (cys C clearance under 30 
ml/min/1.73m2), and all of them had HRS.
In type 1 HRS patients, NT-proBNP levels were signicantly 
higher than in type 2 HRS patients, supporting the claim that 
type 1 HRS patients have a more severe cardiac dysfunction. 
e deceased patients had signicantly higher NT-proBNP 
levels as compared with the surviving patients. All deceased 
patients were in advanced stages of liver cirrhosis (88.8% were 
also diagnosed with HRS), and the onset of renal dysfunction 
and the poor prognosis of these patients were also linked to 
the systolic cardiac dysfunction. 
e onset of cardiac dysfunction was not related to the 
alcoholic or viral etiology of the cirrhosis: no significant 
dierences were found between the NT-proBNP levels in 
alcoholic as compared to viral cirrhosis, evaluated in the 
same stage of disease (non-azotemic cirrhosis with ascites 
and cirrhosis with HRS, respectively). These findings are 
concordant with those of other studies [20].
A prolonged QTc interval was found in over 50% of 
cirrhotic patients and was correlated with the grade of liver 
dysfunction. The life-threatening arrhythmias are rare in 
cirrhotic patients and the prolongation of the QT interval per 
se is not an indication for beta-blocker treatment [20, 22, 23]. 
In our study, the median values of the QTc interval 
were signicantly higher in the HRS group and in patients 
with ascites. A direct correlation of the serum NT-proBNP 
concentration with the QTc interval was found (p<0.001) 
and a negative correlation with the MAP values (p=0.005). 
The circulating NT-proBNP thus correlates with cardiac 
dysfunction, which is more severe in patients with advanced 
liver cirrhosis. 
We must admit that the low number of patients with 
measured QTc interval might have inuenced the signicance 
of the correlations reported. NT-proBNP levels should have 
also been evaluated in correlation with other parameters of 
systolic and diastolic dysfunction.
A significant correlation of the serum NT-proBNP 
concentration with the Child-Pugh score was found, proving 
the link between cardiac dysfunction and liver disease severity. 
is nding is in agreement with the previous reports, which 
found a more frequent and more severe cardiac dysfunction 
in patients with advanced liver disease as compared to those 
with mild liver disease [19, 24].
e systolic cardiac dysfunction of patients with advanced 
liver cirrhosis is an important pathogenetic factor for renal 
dysfunction. e patients with liver cirrhosis having a cardiac 
output <6 l/min and decreased MAP are at high risk of 
developing HRS. Maintaining cardiac contractility is essential 
in preventing renal dysfunction and HRS [25, 26].
The results of our study regarding the significant 
correlations between the NT-proBNP levels and the estimated 
GFR with the MDRD6 formula, cystatin C clearance with the 
Hoek formula are in agreement with the literature data and 
support the cardio-renal interrelation in patients with advanced 
liver cirrhosis. The correlation between the NT-proBNP 
concentration and the GFR proves that the cardiac dysfunction 
present in patients with advanced cirrhosis has an important 
pathogenic role in the development of HRS. e cardio-renal 
interrelation has clear therapeutic implications. Optimizing the 
cardiac output in patients with liver cirrhosis and ascites is an 
important step in HRS prophylaxis and treatment [19, 20, 26]. 
The significant relationship between the NT-proBNP 
concentration and the MELD score found in our study stresses 
the prognostic value of cardiac dysfunction markers, which are 
correlated with patient survival. Similar to other reports, the 
lowest survival rate was found in patients with the most severe 
cardiac dysfunction. e decrease in cardiac output plays a part 
in the onset of the HRS and inuences the poor prognosis of 
the patients with advanced cirrhosis [27].
CONCLUSIONS
e high NT-proBNP levels in our patients with advanced 
cirrhosis indicate the presence of cardiac dysfunction. e 
cardiac dysfunction was correlated with the liver disease 
severity. e correlation between the NT-proBNP concentration 
and the glomerular ltration rate argues in favour of the cardio-
renal interrelation in patients with liver cirrhosis. 
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